Adjuvant pertuzumab improves early breast cancer outcomes

被引：0
|
作者：
Das, Manjulika
机构：
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 07期
关键词：
D O I：
10.1016/S1470-2045(17)30481-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E378 / E378
页数：1
相关论文
共 50 条
  • [1] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [2] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [3] Adjuvant trastuzumab improves survival in early breast cancer
    Brower, Vicki
    [J]. LANCET ONCOLOGY, 2014, 15 (13): : E589 - E589
  • [4] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
  • [5] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    [J]. JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [6] FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
    Howie, Lynn J.
    Scher, Nancy S.
    Amiri-Kordestani, Laleh
    Zhang, Lijun
    King-Kallimanis, Bellinda L.
    Choudhry, Yasmin
    Schroeder, Jason
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Ibrahim, Amna
    Sridhara, Rajeshwari
    Blumenthal, Gideon M.
    Pazdur, Richard
    Beaver, Julia A.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (10) : 2949 - 2955
  • [7] Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?
    Mazzotta, Marco
    Barba, Maddalena
    Pizzuti, Laura
    Vici, Patrizia
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S281 - S284
  • [8] Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
    Lewis, J. D.
    Chagpar, A. B.
    Shaughnessy, E. A.
    Edwards, M. J.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 145S - 145S
  • [9] Excellent Outcomes With Adjuvant Toremifene or Tamoxifen in Early Stage Breast Cancer
    Lewis, Jaime D.
    Chagpar, Anees B.
    Shaughnessy, Elizabeth A.
    Nurko, Jacob
    McMasters, Kelly
    Edwards, Michael J.
    [J]. CANCER, 2010, 116 (10) : 2307 - 2315
  • [10] Adjuvant pertuzumab (PER) for HER2-positive early stage breast cancer (eBC): A Swiss experience
    Stravodimou, A.
    Bodmer, A.
    Lopez, V. Aedo
    Zurcher, J. P.
    Zaman, K.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 92 : S93 - S93
12345